Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dr. August Wolff GmbH & Co. KG Arzneimittel
With
Dr. Dimitrios Chatsiproios
Dr. med. Klaus König
SAM®, Statistische Analysen und Monitoring GmbH
The goal of this application study was to answer the question as to whether the application of WO2085 Moisturising Cream for breast cancer patients undergoing chemotherapy or treatment with anti-oestrogens / aromatase inhibitors can result in an improvement in the subjective symptoms and objective diagnoses of vulvovaginal dryness while also ensuring good tolerability.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women with breast cancer undergoing chemotherapy OR therapy with aromatase inhibitors or anti-oestrogens (either at present or up to 3 months after ending treatment) AND with symptoms of vulvovaginal dryness since the start of tumour treatment
Written declaration of consent for the voluntary participation in the study is present
You may not be if
Women who suffered symptoms of vulvovaginal dryness prior to the start of tumour treatment
Patients undergoing radiation therapy
Patients with other tumours
A current vaginal infection
Medical conditions related to the vulva or vagina
Current additional therapy of vulvovaginal dryness or vulvovaginal atrophy
Women who are not able to participate properly in this study
Current alcohol and/or drug abuse
Pregnant or lactating women
Clareo Health | Investigation on the Efficacy of WO 2085 Moisturising Cream for Breast Cancer Patients Suffering From Vulvovaginal Dryness
